French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Monday announced positive results from the Phase 2 CoTikiS study of Lusvertikimab (OSE-127), an anti-IL7R monoclonal antibody, for the treatment of ulcerative colitis (UC).
Lusvertikimab met the primary endpoint, demonstrating significant improvement in the Modified Mayo Score at both doses tested. The drug also showed positive results on key secondary endpoints, including clinical and endoscopic remission.
The drug was well-tolerated with a favourable safety profile during both the induction and extension periods.
These results position Lusvertikimab as a potential first-in-class interleukin-7 antagonist for the treatment of autoimmune and inflammatory diseases.
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Vanda Pharmaceuticals receives Orphan Drug Designation from FDA for VGT-1849A
Hansa Biopharma reports positive Phase 2 imlifidase results
Gilead Sciences secures positive CHMP opinion for seladelpar in PBC treatment
GSK's Submission for Nucala (mepolizumab) in COPD accepted by US FDA
Evommune presents positive data from EVO756 first-in-human proof-of-concept trial
Rigel Pharmaceuticals' R289 granted US FDA Fast Track designation
Revelation Biosciences secures FDA acceptance for Gemini IND, Phase 1b CKD study set for 2025
Formosa Pharmaceuticals licenses eye drops for Switzerland and Liechtenstein